Egetis Therapeutics AB (publ) (STO:EGTX)
Sweden · Delayed Price · Currency is SEK 5.37
-0.14 (-2.54%)
Aug 1, 2025, 5:29 PM CET
Egetis Therapeutics AB Company Description
Egetis Therapeutics AB (publ), a pharmaceutical company, focuses on projects in late-stage development for the treatment of serious diseases with unmet medical needs in the orphan drug segment.
The company’s products pipeline includes Aladote, a drug to reduce the risk of acute liver injury associated with acetaminophen/paracetamol overdose, which is in phase IIb/III clinical trial; and Emcitate, a drug for the treatment of monocarboxylate transporter 8 (MCT8) deficiency, a debilitating rare disease with no available treatment.
The company was formerly known as PledPharma AB (publ) and changed its name to Egetis Therapeutics AB (publ) in December 2020.
Egetis Therapeutics AB (publ) was incorporated in 2006 and is based in Stockholm, Sweden.
Egetis Therapeutics AB (publ)
| Country | Sweden |
| Founded | 2006 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 40 |
| CEO | Nicklas Westerholm |
Contact Details
Address: Klara Norra Kyrkogata 26 Stockholm, 111 22 Sweden | |
| Phone | 46 86 79 72 10 |
| Website | egetis.com |
Stock Details
| Ticker Symbol | EGTX |
| Exchange | Nasdaq Stockholm |
| Fiscal Year | January - December |
| Reporting Currency | SEK |
| ISIN Number | SE0003815604 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Nicklas Westerholm | Chief Executive Officer |
| Torsten Almén | Founder |
| Dr. Ingemar Lundström Ph.D. | Founder |
| Dr. Louis Joseph Ignarro Ph.D. | Founder |
| Associate Prof. Heidi Brurok | Founder |
| Dr. Rob Towart | Founder |
| Dr. Yilmaz Mahshid Ph.D. | Chief Financial Officer |
| Dr. Katayoun Welin-Berger Ph.D. | Vice President of Operations |
| Dr. Karl Hard Ph.D. | Head of Investor Relations and Business Development |
| Laetitia Szaller L.L.M. | General Counsel and Head of Compliance and ESG |